In order to strengthen current research aims, UCLA CTSI offers opportunities through assistance with grants and career openings to doctors and researchers who align themselves with the goals and methodologies of translational research. Learn more about these services and opportunities below and by viewing this presentation.
UCLA CTSI is committed to encouraging research by providing various funding opportunities for those who are interested in conducting research. By encouraging the growth of independent research and supporting translational team science, UCLA CTSI hopes to fortify the research community with new discoveries designed to deliver practical bedside applications.
See what Funding Opportunities are currently available below.
UCLA Clinical and Translational Science Institute (CTSI) is inviting applications for Catalyst Grants. Catalyst Grants support team-building activities that advance translational science and promote collaborations across disciplines and CTSI institutions. Awards will range from $100 to $5,000, depending on the nature scope of the project.
The next cycle to submit an application is July 1, 2013 - August 1, 2013.
|Chrisandra Shufelt||Cardiology||Estrogen Deficiency and Cardiovascular Disease in Premenopausal Women|
|Heather Jones||Acute Lung Injury and Effects of NAMPT and NAM in Modulating Lung Inflammation|
|Bahman Chavoshan||Medicine/GIM||The role of neuronal nitric oxide synthase (nNOS) in the pathophysiology of COPD skeletal muscle dysfunction|
|Anuja Shah||Medicine/GIM||Metabolic Effect of Different Sources of Dietary Phosphorus|
|James Byrne||Pharmacology||Investigating the Potential of Reprogrammed Pluripotent Stem Cells for Patien-Specific Cellular Immunophenotyping to Differentiate Infection from Rejecting in Inestinal Transplantation|
|Laura Wozniak||Pediatrics||Develpment of Peer-Led Smoking Cessation|
|Elizabeth Bromley||Psychiatry||Intervention for Individuals with Severe Mental Illness|
|Denis Evseenko||Orthopaedic Surgery||Inhibition of the lysophoshatidic acid signaling as a novel strategy for restoration of posttraumatic cartilage|
|Edward Lee||Radiological Sciences||Potential application of Irreversible Electroporation (IRE) in the treatment of pancreatic cancer|
|Yoon-Hee Cha||Neurology||Functional Neuroimaging and Neuromodulation in Mal de Debarquement Syndrome|
|Paul Tumeh||Medicine/Dermatology||A Needle-Free Nanovaccine Against Melanoma|
|Thao Nguyen||Medicine/Cardiology||Fibrosis, Stress, and Ventricular Arrhythmias|
|Elain Reed||Pathology||UCLA & Roche Collaboration to Use Next-Generation, High-Throughput Screening to Characterize Varialble Receptor Reperitories of T Cells and Natural Killer Cells|
|Roy Doumani||Pharmacology||BSC-CTSI University Entrepreneurship Seminar Series|
|Oliver Hankinson||Pathology||Support for Meetings of the UCLA Molecular Toxicology Program|
|Elizabeta Nemeth||Medicine/Pulmonary||Estrogen Deficiency and Cardiovascular Disease in Premenopausal Women|
|Karen Lyons||Orthopaedic Surgery||Regenerative Musculoskeletal Medicine Training Program Seminar Series|
|James Wascheck||Psychiatry||Immunology in Neuroscience Mini-symposium|
|Carol Mangione||Medicine/GIM||Scientific Retreat, Co-sponsored by UCLA/DCU RCMAR/CHIME, CUD/UCLA Project EXPORT, and UCLA CTSI|
|Gerald Kominski||Public Health||Los Angeles County Community Health Profile Project:A "Hot Spt" Analysis|
|Genhong Cheng||MIMG||25-Hydroxycholesterol and its Analogs as Novel Broad Antiviral Agents|
|Steve Horvath||Human Genetics||Diagnostic and prognostic biomarkers for HIV-Associated Non-AIDS (HANA) condition|
|Debika Bhattacharya||Medicine/Inf Dis||Cardiovascular and Metabolic Complications of HIV/HCV Co-Infection|
|Linda Liau||Neurosurgery||Immune and Gene Therapy|
|Yibin Wang||Medicine/Cardiology||Systems Genetics of Heart Failure: Paving the Road to Translation|
UCLA (1) Winter 2012
|Christian Roberts||Endothelial Progenitor Cell Quantification in Smokers by a Novel Gating Strategy: Effects of Resistance Training and Nicotine Replacement|
|Timothy R Donahue||Targeting the chemotherapy-resistant epigenetic reprogramming of stromal cells in human pancreatic cancer|
|Andrew Dean||Neurobehavioral Predictors of Cognitive Decline in Methamphetamine Dependence|
|Philip Liu||Defining M. tuberculosis virulence through the genomic interactome|
|Joanna Schaenman||Analysis of immune control of BK virus replication after kidney transplantation|
|Jeffrey L. Veale||Monitoring Renal Allograft Dysfunction by Utilizing a Multiplexing Electrochemical Sensor to Measure Combinational Biomarkers: Creatinine and Cystatin-C|
|Sanaz Memarzadeh||Preclinical trial to assess effectiveness of PARP inhibitors in targeting endometrial cancer|
|Zoran Galic||Gene expression analysis of the hESC-derived T lineage cells|
|Daniel Cruz||Deciphering human innate immune networks governed by the microenvironment|
|Edmond H. Teng||Validation of Plasma Biomarkers for Alzheimer's Disease in an Animal Model|
|Brent Fogel||Rare and Novel Genetic Variation in Cerebellar Ataxia|
|Sepideh Hagvall||De-differentiated fat as a cell source for cardiovascular tissue engineering|
|Laura Wozniak||Unique Adaptive and Innate Immune Cell Profiles in Tolerant Pediatric Liver Transplant Recipients|
|Susan Krum-Miranda||Estrogen-dependent control of osteoblast-derived collagen architecture|
|Richard C. Koya||Study of advantageous phenotypic changes in T cells for adoptive cell transfer therapy for melanoma induced by the mutant BRAF inhibitor vemurafenib|
|Sophie Deng||Bioengineering of human limbal stem cells|
|Fang Wei||Non-invasive detection of exosomal Lung Cancer EGFR gene mutations by Electric Field Induced Release and Measurement (EFIRM)|
|Denis Evseenko||Isolation and characterization of human cartilage progenitors|
|Eileen Tsai||Identification of Plasma Proteins from Biomarker Candidates that Predict Acute Rejection and Monitor Non-adherence in Pediatric Renal Transplantation|
|Paul Camille Tumeh||A High Throughput Platform to Identify Small Molecules that Enhance T-cell Mediated Melanoma Immunotherapy|
|Stephen Bensinger||Determining the influence of SREBP on HCV pathogenesis|
|Giovanni Coppola||Using Induced Pluripotent Stem Cell-Derived Neurons to Understand C9ORF72-mediated neurodegeneration|
|Alistair J. Cochran||Genetic basis of the biology of melanoma metastases|
|Betty P.T. Tsao||Establishment of relational databases for lupus genetic study|
|Cathy Lee||Metabolic Effects of Androgenicity in Aging Men and Women|
|Daniel Geschwind||Treatment of autism-related behavior in the Cntnap2 knockout mouse model|
|Danny JJ Wang||Virtual Lumbar Puncture using MRI|
|Donald Kohn||High Through-Put Screening to Improve Gene Transduction of Human Hematopoietic Stem Cells|
|Elizabeta Nemeth||New drug leads for iron overload|
|Eric Hoek||High Throughput Screening of Infection Resistant Coating Films|
|Eric Vilain||Improving Diagnosis of Disorders of Sex Development by Whole Exome Sequencing|
|Fritz Eilber||Preclinical Imaging of Genetically Engineered and Direct-Patient Xenograft Models of Malignant Peripheral Nerve Sheath Tumors|
|Gal Bitan||A mouse toxicity study of a novel drug candidate|
|Jonathan Braun||Mucosal proteome in HIV infection|
|Lee Goodglick||Construction of a Triple Negative Breast Cancer Tissue Array for Translational Research|
|Patricia A. Ganz||Young Breast Cancer Survivorship Program|
|Roger Lo||Integrated genomic analysis of melanoma response to BRAF inhibition|
|Ronald Mitsuyasu||CFAR/UCLA HIV Research Study Volunteer Project|
|Timothy R Donahue||Targeting the chemotherapy-resistant epigenetic reprogramming of stromal cells in human pancreatic cancer|
Charles Drew University (1) Winter 2012
|Amira Brown (CDU)||Evaluating dopaminergic gene expression in subcortical brain regions of C57BL/6J and DBA/2J mice|
|Shehla Pervin (CDU)||Targeting pERK1/2 in Mammary Cancer Stem Cells|
|John Elshimali (CDU)||Epigenetic examination of potential genes involved in drug resistance in different types of prostate cancer cells|
Cedars-Sinai (1) Summer 2012
|Bekir Cinar||Evaluation of Tumorigenesis by Optical Imaging in Live Animals|
|Yelena Bykhovskaya||High-throughput sequencing of linkage region in multi-generational family with dominant keratoconus|
|Melodie Metzger||The Relationship between Experimental Serum Vitamin D Levels and Spinal Fusion Strength: a Quantitative Analysis|
|Ke Cheng||Identification of the functional ingredient(s) of cardiosphere-derived cells|
|Viorica Ionut||The role of gut-brain communication in type 2 diabetes (T2DM) and in T2DM remission after bariatric surgery using fMRI|
|Wen Chin Huang||SREBP-1/ROS/AR signaling Promotes Prostate Cancer Castration-resistant Progression|
|Vaithi Arumugaswami||Hepatitis C Virus Clinical Isolates From HCV-HIV Co-infected Patients for Vaccine Development.|
|Philip Frykman||Fungal Microbiome in Children with Hirschsprung Associated Enterocolitis|
|Bill Wilcox||High-throughput Drug Screening to Find a Small Molecule Treatment for Achondroplasia|
|Hyung Kim||Development of Prostate MRI for Active Surveillance|
|Biagio Saitta||Generation of Induced Pluripotent Stem Cells to Create In Vitro Model of Skeletal Dysplasias.|
|Miklos Peterfy||In vivo validation of novel genes in lipid metabolism and coronary artery disease|
|Rivkah Gonsky||Functional Relevance of Epigenetic Modifications in IBD|
|Mark Pimentel||Deep Sequencing the Small Bowel Microbiome: Role in Human Disease|
|Robert Barrett||Generation of induced pluripotent stem cells from CrohnåÕs disease patients using EBV transformed B-cell lines.|
|Sandra Orsulic||Development of an Assay to Predict Outcome in Multiple Cancer Types|
LA-BioMed-Harbor UCLA (1) Summer 2012
|Lin Lin||Differentiation pluripotent stem cells into mature neutrophils|
|Peter Liu||Testosterone and estradiol pulsatility in men with OSA|
|Tsui-Fen Chou||Quantitative Cell-based Screens to Identify Drugs and Targets Within the Ubiquitin-Proteasome System|
|Rebecca Stockton||In Vivo Cerebrovascular Imaging of Mouse Cerebral Cavernous Malformations|
|Kevin Bruhn||Subversion of Host Defense Pathways by Visceralizing Leishmania Species|
|Michael Yeaman||Innovative Anti-Infective Agents & Strategies|
|Ashraf S. Ibrahim||Molecular Diagnostics of Mucormycosis|
|Noah Craft||Treatment of Visceral Leishmaniasis with Topically Applied TLR Agonists|
|Yan Xiong||Early agr activation is a key pathogenic signature in persistent MRSA bacteremia|
|Yanhe Lue||Histone Demethylase in XY and XXY Male Germ Cells|
UCLA (2) Fall 2012
|Roger Lo||Whole-exome sequencing of single circulating melanoma cells: tumor heterogeneity and BRAF targeted therapy.|
|Satiro De Oliveira||Anti-leukemic Immunotherapy Using Modification of Hematopoietic Stem Cells|
|Jorge Torres||Inhibition of STARD9 in Cancer|
|Amy C. Rowat||Cancer Prognosis and Treatment by High Throughput Mechanical Screening|
|Kara Calkins||Fish Oil: A Novel Therapy for Pediatric Intestinal Failure Associated Liver Disease|
|David Shackelford||Develop novel therapeutic strategies to target LKB1/STK11 deficient non-small cell lung cancer|
|Zhong Zheng||Silver nanoparticle coated titanium: an antimicrobial and osteoinductive material for orthopedic device fabrication|
|Heather R. Christofk||Role of MCT1 in cancer metabolism|
|Pascal F. Egea||Structure-Based Discovery and Design of Novel Anti-malarials|
|Reza Ardehali||A clonal analysis approach for cardiovascular regeneration|
|Erina Vlashi||Role of Erythropoietin in Breast Cancer Stem Cells|
|James Byrne||Pre-clinical transcriptional analysis of human osteogenic dermal mesenchymal stem cells|
|Matthew Shtrahman||Development of a Novel Test for Seizure Threshold|
|David Brooks||IMMUNE RECONSTITUTION DURING PERSISTENT VIRAL INFECTION|
|Aydogan Ozcan||Metallic Nanoparticles Enhanced Recognition of CD4+ T Cells by Lensfree On-Chip Imaging|
|Debora Farber||Microarray analysis of genes involved in retinal pigment epithelium melanogenesis, a process that is abnormal in ocular albinism.|
|Xiangdong William Yang||Cell-based screening for disease modifying chemical compounds for HuntingtonåÕs disease|
|Jane Deng||Correlation between alterations in gene expression and the nasal microbiome following viral infections|
|Jau-Nian Chen||In vivo chemical suppressor screen for cardiac arrhythmias and heart failure.|
|Dino DiCarlo||Role of biomechanical single-cell analysis in the diagnosis and treatment of cancer stem cells|
|Eric Hoek||Antibacterial Self-Doped Polyaniline Coating Films For Biofouling Control On Medical Devices|
|J. David Jentsch||Identifying Genomic Loci Influencing a Translational Measure of Risk-Taking Temperament|
|Leonard H. Rome||Vault Nanoparticle Immunotherapy for Lung Cancer|
|Christopher S. Colwell||Non-dipping hypertension in HuntingtonåÕs disease|
|David B. Reuben||Facilitating Community Services for Dementia Patients|
|Katherine Narr||Biomarkers of Ketamine response in Major Depression|
|Mario Deng||Comprehensive Biomarker-based Classification of the Endomyocardial Biopsy|
|Rachelle H. Crosbie-Watson||A novel gene therapy approach for treatment of cardiomyopathy|
|Yin Tintut||Regulation of PTH-induced Osteoanabolism by Inflammatory Lipids|
|Theodore F. Robles||Using LC-tandem mass spectrometry to identify salivary biomarkers predicting post-traumatic stress disorder in trauma patients|
|Asim Dasgupta||A Novel Anti-viral Approach using Thymidine Kinase Monoclonal Antibody|
|Berit Kerner||Exome å–Sequencing in Bipolar Disorder|
|Kang Ting||Fibromodulin reprogrammed cells for bone regeneration|
|Larry F. Hoffman||Oxidative stress and neuroprotection in inner ear sensory epithelia|
|Robert T. Clubb||Screen to discover novel Anti-infective agents|
|Yousang Gwack||Calcium signalling and epigenetics in T cells|
|Charles Drew University (2) Fall 2012|
|Satyesh Sinha||Effect of M-CSF/GM-CSF ratio on macrophage polarization in Diabetic Nephropathy|
|Piwen Wang||Protein targets towards an increased inhibition of prostate tumor growth in SCID mice by a combination of green tea and quercetin|
LA-BioMed-Harbor UCLA (2) Fall 2012
|Soo Jin Yang||The role of the LytSR sense-response system in resistance to cationic antimicrobial peptides in Staphylococcus aureus|
|Michelina Iacovino||HoxA3 and heart development|
|Kevin Bruhn||Resiquimod as an Alternative Treatment for American Tegumentary Leishmaniasis|
|Tsui-Fen Chou||Identification of biomarkers of p97 inhibition for anti-p97 cancer therapy|
|Christina C. L. Wang||Influence of testosterone on non-alcholic fatty liver disease in men|
|Patricia Dickson||Biomarkers for Mucopolysaccharidosis|
|Scott G. Filler||Candida Invasion of Endothelium and Virulence|
James A. McKinnell, MD
Assistant Professor of Medicine
LA BioMed at Harbor-UCLA
Project title: Using Research in Vancomycin-Resistant Enterococcus to Validate an Efficient System of Quantifying Antibiotic Utilization
Loren G. Miller, MD, MPH – LA BioMed at Harbor-UCLA
Susan S. Huang, MD, MPH – UC Irvine
Martin F. Shapiro, MD, PhD – UCLA
Infectious Disease, Health Services Research, Clinical Trials, and Clinical Outcomes Research
Approximately 100,000 Americans die every year from infections acquired in hospitals. HAI due to Vancomycin-resistant Enterococcus spp. (VRE) are of particular concern. VRE HAI’s disproportionately affect the most immunocompromised hosts, such as organ transplant recipients, and the severely immunosuppressed. Each VRE bloodstream infection (VRE-BSI) is associated with $50,000 of additional healthcare costs and a 35% attributable mortality. The purpose of this investigation is to 1) evaluate the association between antibiotic use and VRE-BSI incidence, 2) investigate VRE-BSI outcomes using improved methodologies, and 3) validate an electronic source of patient-level antibiotic usage data that can be used for investigations of VRE-BSI and further research on other important pathogens.
Dr. McKinnell will work to develop a database to evaluate the association between antibiotic use, VRE-BSI incidence, and outcomes of patients with VRE-BSI from data derived from Ronald Reagan Medical Center. He will also lead efforts to conduct a retrospective chart review to define the predictors of treatment success among hospitalized patients with VRE-BSI and validate the antibiotic database.
Mary E. Sehl, MD, PhD
Assistant Clinical Professor of Medicine
Division of Hematology-Oncology, UCLA
Project title: Modeling of EMT/MET transitions in breast cancer stem cells
Kenneth Lange, Ph.D. - UCLA
Gay Crooks, M.B.B.S. - UCLA
Max Wicha, M.D. – University of Michigan
biomathematics, oncology, cancer stem cells
Breast cancer is the most common type of cancer diagnosis in women, with the majority of deaths caused by distant recurrence.
Stem cell-targeted therapies offer new hope in eradicating breast cancer stem-like cells that lead to recurrence after standard therapies fail. Mathematical models have proven useful in studying the population dynamics of cancer stem cells under targeted therapy and are informative in assessing safety and duration of therapy. However, the complexities of the stem cell microenvironment limit the predictive ability of analytic models and suggest the necessity of more informed modeling strategies.
Stochastic simulation methods model rare events that are important in cancer modeling, such as extinction and mutation, and have the ability to address complex dynamics and incorporate feedback of reaction networks in systems biology. We postulate a model in which breast cancer stem-like cells freely convert between an epithelial (proliferative) and mesenchymal (quiescent, invasive) state, through epithelial-to-mesenchymal transition (EMT) and the reverse process (MET). The mesenchymal state is identified by CD44, a marker of cell adhesion and invasive potential, while epithelial stem cells can be CD44 negative and express ALDH, a marker of mammary stem cells and predictor of poor clinical outcome (6). Cytokines such as IL-6 and TGF-beta, as well as intracellular signaling and miRNAs, may regulate the interconversion of breast cancer stem-like cells between EMT-like and MET-like states.
We propose a combination of theoretical modeling with experimental validation to study the rates and regulators of EMT/MET transitions in breast cancer stem-like cells. We apply our model to predict alterations in stem cell populations and their regulatory pathways in response to niche-targeted therapy. Ultimately, predictions of therapeutic efficacy and safety could be validated in clinical trials and used to guide drug development and plan therapy duration. We envision that extinction models will provide a novel approach to therapeutic design.
David Shackelford, PhD
Assistant Professor of Medicine
Division of Pulmonary and Critical Care Medicine, UCLA
Project title: Development of novel therapeutic strategies to target LKB1/STK11 deficient non-small cell lung cancer
Steven M. Dubinett, MD – UCLA
Hong Wu, MD, PhD – UCLA
Translational cancer research, signal transduction, metabolism, lung carcinogenesis, genetically engineered mouse models of lung cancer, micro PET-CT imaging
My project focuses on identifying and testing novel therapies for the treatment of early stage LKB1-deficient lung tumors. The LKB1 tumor suppressor functions as a master regulator of cellular growth, metabolism and survival. Importantly, the LKB1 gene is frequently mutated in ~35% of non-small cell lung cancer (NSCLC) however, the molecular mechanisms driving tumor growth following LKB1 mutations are poorly understood and to date there are no therapies that target LKB1-deficient lung cancer. As more targeted therapeutics for NSCLC are needed, I explored use of biguanides, traditionally used to treat diabetes, as metabolic stress agents to target LKB1-deficient lung tumors. At a cellular level, LKB1-deficient tumor cells are unable to respond to energy stress and selectively undergo increased apoptosis following treatment with metabolic stress agents such as biguanides. The selective sensitivity of LKB1-deficient tumors to metabolic stress presents an Achilles heel to exploit and opens a therapeutic window from which to target LKB1-deficient cells. Additionally, loss of the LKB1 gene results in elevated mTOR signaling that results in increased tumor growth and proliferation. My project will investigate the use of biguanides (metformin or phenformin) in combination with targeted mTORC1 inhibitors (rapamycin or INK128) for the treatment of LKB1-deficient NSCLC. I will perform preclinical studies using genetically engineered mouse models of lung cancer to assess the efficacy these novel drug combinations in vivo. Using micro 18FDG-PET and bioluminescence imaging in combination with detailed immunohistochemical and biochemical analysis I will dissect the molecular signaling pathways driving tumor growth and survival in LKB1-deficient lung tumors. With this multifaceted approach I aim to uncover novel pathways that can be exploited therapeutically in LKB1-deficient tumors. My overarching goal is to identify new, clinically relevant therapeutic strategies to treat patients with NSCLC harboring LKB1 mutations.
|Amira K. Brown, PhD
Department of Internal Medicine
Charles Drew University of Medicine and Science
Project: Effects of varenicline on alcohol and nicotine consumption and changes in dopamine d2-like receptor availability in high-alcohol-preferring mice
Theodore Friedman, MD, PhD - Charles Drew University of Medicine and Science
Mark Mandelkern, MD, PhD - VA Greater Los Angeles Health System
Endocrinology, Medical Physics, Pharmacology, Psychology
Dopamine is a chemical in the brain with many important functions. This project aims to understand the role of the dopamine receptor system in concomitant alcohol and nicotine abuse and treatment.
The project specifically focuses on the d2 dopamine receptor, which is involved in reward-seeking behavior. Lower d2 dopamine receptors have been shown in animal models of addiction and substance abusers.
Positron emission tomography (PET) will be used to characterize the dopamine d2 receptor profile in the brains of high-alcohol-preferring (HAP) and low-alcohol-preferring (LAP) mice. We expect that HAP mice will have significantly lower dopamine d2 receptor availability in an area of the brain called the striatum when compared to LAP or normal, wild-type mice.
This study also will examine the effects of varenicline, a smoking-cessation drug, on dopamine d2 receptor availability, nicotine and alcohol consumption in HAP and LAP mice. HAP mice will increase their voluntary alcohol consumption following chronic nicotine exposure; that increase will be related to decreases in striatal d2 receptor availability. However, following varenilcine treatment, HAP mice exposed to chronic nicotine are expected to decrease their voluntary intake of alcohol; that decrease in alcohol intake will be related to increases in dopamine d2 receptor availability.
Results from this study will provide important scientific and clinical information regarding the role of the dopamine receptor system in the underlying mechanisms of comorbid alcohol and nicotine preference. Moreover, finding an effective pharmacotherapy for this addiction is crucial; as such, the project will determine whether changes in dopamine receptors are involved in the efficacy of varenicline treatment success.
Joshua J. Zaritsky, MD, PhD
Pediatrics Division of Pediatric Nephrology
Mattel Children's Hospital, UCLA
Project: Hepcidin and the anemia of chronic kidney disease
Isidro Salusky, MD - UCLA
Tomas Ganz, MD, PhD - UCLA
Kamyar Kalantar-Zadeh, MD, MPH, PhD - LA BioMed at Harbor-UCLA Medical Center
Erythropoiesis-stimulating agents (ESA)(drugs used to spur red blood cell production), are an important component of anemia therapy in patients with chronic kidney disease (CKD). ESA hyporesponsiveness, however, occurs frequently and is often associated with iron deficiency and inflammation as well as poor outcomes. Given the urgent need to explore novel approaches that can allow ESA dose reduction as recently recommended by the FDA, it is crucial to understand the molecular mechanisms that link inflammation, iron balance and erythropoiesis in CKD. Hepcidin, a protein produced in the liver, is a key regulator of iron homeostasis. Preliminary data indicates that hepcidin accumulates in CKD, making it likely that hepcidin plays a major role in the anemia of CKD as well as ESA hyporesponsiveness.
This project aims to expand our knowledge of hepcidin biology in the setting of CKD. It will examine two hypotheses: (1) Does progressive loss of kidney function directly lead to increased hepcidin levels? and (2) Do these increased hepcidin levels contribute to iron restriction and anemia in experimental animals with CKD?
This project will provide crucial knowledge as to whether hepcidin contributes to the anemia of renal disease and ESA hyporesponsiveness and thus will help to optimize anemia treatment of CKD.
Gelareh Z. Gabayan, MD, MSHS
David Geffen School of Medicine
UCLA VA Greater Los Angeles Health System
Project: Patterns and predictors of poor outcomes following emergency department discharge in older adults
Catherine A. Sarkisian, MD, MSPH - UCLA
Arthur Kellermann, MD, MPH - RAND
Jerome R. Hoffman, MD, MA - USC
Emergency Medicine, Geriatrics, Health Services Research
This project assesses Emergency Department (ED) quality and patient safety by evaluating the factors associated with poor outcomes following an ED visit. In collaboration with Kaiser Permanente Southern California and using a case-control study design, this study will identify the patterns and predictors of short-term mortality or an ICU admission following discharge from the ED in older adults. The ultimate goal of this project is to reduce the incidence of preventable poor outcomes following discharge from the ED through the implementation of feasible and practical Emergency Department systems-based interventions.
|Project Title||UM Scholar||UCLA Scholar|
|Alzheimer's Disease Coordinated Care for Hispanic and Latino Seniors||Josheph E. Gaugler||Joshua Chodosh|
|HIE Use in Small- and Medium-Sized Primary Care Practices: Understanding & Eliminating the Disparity||William Riley||Hector Rodriguez|
|Correlation of Early Childhood Caries Risk and Obesity in Preschool Age Children Via Salivary Testing||Robert Simon Jones||Francisco J. Ramos-Gomez|
Request for Applications from Investigators at all CTSI partner institutions (UCLA, Cedars-Sinai, Harbor-UCLA/LA-BioMed, Charles Drew University)
CTSI periodically awards vouchers to defray the cost of core services. Under this RFA, the CTSI will award vouchers to investigators at all CTSI partner institutions (UCLA and Charles Drew University up to 30 vouchers, Cedars-Sinai up to 15 vouchers, and Harbor-UCLA/LA-BioMed up to 8 vouchers) worth up to $10,000 in core services.
Click here for details.
Junior Faculty Mentored-Research Awards are available for junior faculty in any series within their first three years of appointment to support mentored training in translational research in all areas of investigation. Grants of a maximum of $30,000 will be awarded for a one-year period. Funding from this program cannot be used to support the PI’s salary. Applications will be accepted from MD or PhD junior faculty in any series at UCLA CTSI partnered and affiliated institutions, within their first 3 years of appointment.
The criteria for the selection include quality of the scientific proposal, the candidate’s potential for an independent translational research career, potential translational impact of the research and relevance to the overall translational research mission of the UCLA CTSI. Awarded Scholars will participate in CTSI research education and career development opportunities. Scholars will complete an annual progress report as part of their award requirements.
Team Science Awards support multidisciplinary team-based research that addresses major health problems in our community. These awards enable researchers to obtain preliminary data in order to apply for extramural research grants. Since the program was initiated, we have partnered with departments and centers to fund 8-10 Team Science Awards ranging from $25,000 - $200,000/year. We are striving to leverage our resources in this area so that we can fund up to 8 grants annually.
CTSI has offered Team Science Awards in autism, cancer, cardiovascular medicine, HIV/A/IDS, neuroscience and women's health, among other research areas. If your area of research addresses a major health problem in our community, it may be eligible for a Team Science grant. A letter of intent (LOI) from your Organization (e.g., Department, Organized Research Unit (ORU), Center) representing a specific disease area in clinical translational science should be addressed to Dr. Kavitha Rajavel, Technology Officer, CTSI, to initiate the process.
The LOI must provide
Please note that all CTSI Team Science Awards must have a formal RFA that is disseminated widely to the open research community, and all proposals must be competitively peer reviewed.
The UCLA CTSI KL2 Translational Science Award supports highly qualified junior faculty to conduct mentored, interdisciplinary, patient-oriented research. The program is specifically designed to meet an important goal of the UCLA CTSI: To provide the next generation of clinicians with the training they need to conduct research across engineering, physics and other disciplines to improve health.
Please refer to the Application guidelines for detailed information.
CTSI supports the Business of Science Center Venture Team Program, which pairs faculty inventors with graduate students from such areas as law, business, medicine, life science, physical science and engineering. The teams compete for proof-of-concept awards, which are partly funded by CTSI. More information about the Venture Team Program can be found here.
The Clinical and Transitional Research Center (CTRC) at the Westwood campus provides nursing, nutrition and laboratory support for outstanding clinical research at all stages—phase I studies to multi-center trials. With the recent successful application and funding of the CTSI grant (NCATS UL1TR000124), the CTRC is a newly renovated state-of-the-art research center that, in addition to our inpatient 6W unit in the Ronald Reagan UCLA Medical Center, provides superior service to investigators.
The CTRC has three broad goals: (1) Transition from research-related clinical care funded by the General Clinical Research Center (GCRC) grant (ended 6/31/11) to a model of shared costs between the primary NIH (or similar non-profit) grant of the Investigator and the CTRC, (2) Maintain the ability to provide all forms of research-related clinical care, and (3) Develop a fiscal model that can be sustained without external funding and allows growth of the clinical and translational research mission.
The CTRC Seed Grant Program is designed to foster pilot studies that use CTRC facilities and staff as well as its full range of cost-effective laboratory testing in the Clinical Translational Research Laboratory (CTRL). See http://www.ctsi.ucla.edu/ctrc.
This call for seed grant proposals seeks to establish collaborations between UCLA investigators and the CTRC in four categories:
These Seed Grant Awards are expected to (1) lead to larger projects that will be appropriate for independent funding from a government agency or private foundation, (2) make significant use of the Westwood CTRC services, especially nursing and nutrition, and (3) result in at least one peer-reviewed publication.
To apply, applicants or mentors must hold a UCLA faculty position; faculty at UCLA affiliate institutions (e.g., WLVAMC, CSMC, Harbor-UCLA) are eligible. Collaboration with researchers at the Westwood campus is encouraged and can be facilitated if needed. Researchers or emerging investigators focused on health disparities and/or disabilities are encouraged to apply.
For more information view the entire RFP here.
APPLICATION DEADLINE: March 25, 2013 (Monday 5 pm)
FUNDING AMOUNT: $25,000 per project (direct costs)
BUDGET PERIOD: June 1, 2013 – May 31, 2014
The UCLA Center for Autism Research and Treatment (CART) invites applications for grants to fund pilot and/or feasibility studies for biomedical, epidemiological or behavioral research. This funding is made available through the National Institutes of Health (NIH) Autism Centers of Excellence (ACE) program which funds the UCLA CART, with Semel Institute departmental “Autism Initiative” funds to CART, and by collaborative funding from the UCLA Clinical and Translational Science Institute (CTSI). The UCLA CART is an ACE Center, and also leads two ACE Networks, as funded by NIH as part of a nationwide set of research programs. The UCLA center’s activities are wide-ranging and include the integration of clinical, imaging, genetic, and basic science research to create a synergistic milieu that maximizes the productivity of the participants and attracts other investigators to the field of autism.
PURPOSE: The purpose of these awards is to foster interactions and interdisciplinary research projects in the basic and clinical areas of autism. Preference will be given to projects that are likely to lead to successful future funding (by R01-type awards, etc). Proposals addressing the mechanism and treatment of autism are encouraged. Projects can also build upon the UCLA CART’s mission and current research activities; descriptions of CART’s mission and research, including the previously funded pilot grants, and this announcement are available at our website www.autism.ucla.edu.
ELIGIBILITY: Funds are available to the UCLA academic community including new investigators, investigators from other fields willing to bring their research expertise to autism studies, and for investigators whose proposed research would constitute feasibility testing. Funds are not intended to supplement ongoing supported research of an established investigator. Postdoctoral fellows are eligible only if they have a UCLA appointment by June 1, 2013 and provide documentation of support of a faculty sponsor (who must serve as the Co-PI on the grant application), confirmed space allocation and a UCLA appointment, each through the entire award period.
AWARD TERMS: These pilot project awards are for one-year only and are limited to $25,000 (direct costs) per project. Funds will not be awarded for equipment costs or for salary or benefits for the principal investigator, postdoctoral fellow or any study personnel who hold an academic appointment. An investigator is eligible only once for the pilot support unless the additional proposed study constitutes a substantial departure from the previous research. All applications involving humans or animals must have IRB or ARC approval at UCLA or an UCLA-affiliated institute before the funds will be released. The funding period for 2013 awards is June 1, 2013 – May 31, 2014.
APPLICATION GUIDELINES: The proposals must present a testable hypothesis, clearly delineate the question(s) being asked, detail the procedures to be followed and discuss how the data will be analyzed. Specifically, the proposals may be up to 5 pages and must include: Abstract (250 words or less), Specific Aims, Background, Preliminary Studies, Experimental Design and Methods, and Significance. In addition, the literature references should be attached along with the following NIH (PHS 398) standard forms: the investigator’s 2-page biographical sketch, budget with detailed justification, and other outside funding support. If funded, the investigator also will need to provide a summary of the project in lay language and be willing to present the findings at CART & CTSI lectures and meetings.
Please submit 3 hardcopies (and email the complete application as one PDF) of your application on or before March 25, 2013 (Monday, by 5 pm) to CART’s Director of Operations & Outreach:
Candace J. Wilkinson, Ph.D., Semel/NPI Institute, Room 68-237; 760 Westwood Plaza; Los Angeles, CA 90024. If you have questions, you may contact Dr. Wilkinson at 310.825.9041 or e-mail: firstname.lastname@example.org
Full CART announcement can also be found here.
Pilot Funding for Research in Women’s Health
The Iris Cantor-UCLA Women’s Health Center Executive Advisory Board / CTSI Award
Funding Amount available: $30,000 one year pilot awards for all types of research
Full RFP details are attached and available here. (Invitees Only) Pilot proposals will be due March 25. 2013 at 5pm PST.
Fellowship Funding for Research in Women’s Health
The Iris Cantor-UCLA Women’s Health Center / CTSI Young Investigator Award
Funding Amount available: $20,000 one year fellowship
Full RFP details are attached and available here.
Submission: Online CTSI website at http://www.ctsi.ucla.edu/Awards/TSATansNeuro/tsa-neuro-view
Date & Time: Proposal should be submitted by 5:00 pm PST on April 1, 2013.
Grant Description: The Neuroscience/CTSI community is accepting applications for Team Science Award in Translational Neuroscience from research teams at CTSI partner and affiliate institutions to conduct multidisciplinary, team-oriented and high-impact research in the area of neuroscience. Each research team will receive up to $100,000 from CTSI to be matched by an equal amount in matching funds shared by the UCLA Brain Research Institute, the Departments of Neurobiology, Neurology, Neurosurgery and Psychology, and the Semel Institute for Neuroscience and Human Behavior. The award provides maximum support of up to $200K for one year for salary support, benefits and research supplies. We intend to fund 1-2 proposals.
Team Science Award in Translational Neurosciences
The Neuroscience Community in collaboration with the UCLA Clinical and Translational Science Institute is pleased to announce the UCLA Neuroscience/CTSI Team Science Award in Translational Neurosciences for research teams from CTSI partner institutions (UCLA, Cedars-Sinai, Charles Drew University, LA-Biomed) and CTSI-affiliated institutions (RAND, Olive View UCLA Medical Center, Santa Monica UCLA Medical Center, VA Greater Los Angeles Healthcare System) to conduct novel, multidisciplinary, team-oriented and high-impact research in the area of neuroscience. The Team Science Award in Translational Neurosciences is intended to catalyze team science among CTSI partner and affiliate institutions to plan for submission of large extramural grants. Neuroscience related disorders and diseases represent a major challenge in health care with limited therapeutic options. This initiative is specifically designed to meet an important goal of the UCLA CTSI: To support emerging, high-impact, multidisciplinary research programs that aim to tackle the multi-factorial complexity in the mechanisms and manifestations of the diseases, and to promote accelerated translation between basic science research and clinical practice.
Who May Apply:
The Neuroscience/CTSI Team Science Award seeks to fund new research teams of established investigators utilizing innovative, shared research approaches, tools, models and concepts to bring a new paradigm to our current understanding and to have a transformative impact in the field.
Submission Guidelines: (must use standard NIH page setup and font requirements)
The applicants must specify the exact extramural funding mechanism being targeted and application deadline (e.g., NHLBI P01 for June 1, 2013). Applicants must identify specific CTSI resources to be utilized and explain how the proposed research is translational. Progress reports and end-of-project reports will be required; templates will be provided. Presentations of posters at BRI and CTSI-sponsored meetings are encouraged. Successful applicant Co-PIs must provide their field of specialization and their NIH Commons ID.
CTSI Specific Requirements:
Prior to transfer of these funds, appropriate IRB/ARC approvals must be in place. In accordance with NIH policy, please amend your relevant IRB and/or ARC protocol to disclose funding support from the UCLA CTSI Grant number UL1TR00124; please submit copies of your IRB, and/or ARC approval to Kavitha Rajavel, (KRajavel@mednet.ucla.edu).
The continued funding of the CTSI grants is dependent on the program’s success. For this reason, it is important that any publications (journal articles, websites, papers, testimonials, etc.) resulting in whole or in part from this project should acknowledge support from both by including the following statement: “This project received support from both the NIH/NCATS UCLA CTSI Grant Number UL1TR000124”. Please notify the CTSI of any subsequent extramural grant support obtained that is relevant to this grant funding.
Proposals must include budget and budget justification using NIH format, including personnel costs, specific planning activity costs and other support for key personnel. No indirect costs are allowed.
Funding will start on July 1, 2013 upon approval from CTSI and after all required documents are received by the Brain Research Institute. The award period will be for one year.
How to Apply:
Online CTSI website at http://www.ctsi.ucla.edu/Awards/TSATansNeuro/tsa-neuro-view
Please address questions related to this RFA, to Ms. Terry Novorr at email@example.com
UCLA Brain Research Institute (BRI)
695 Charles E. Young Drive South #1506
Los Angeles, CA 90095
(310) 825-5062 (Phone)
(310) 206-5855 (Fax)
Full RFA details are available here:
About UCLA/CDU RCMAR/CHIME & the UCLA CTSI
The UCLA/CDU RCMAR/CHIME and the UCLA CTSI are based in the David Geffen School of Medicine at UCLA. RCMAR/CHIME is funded under NIH/NIA Grant Number 2P30AG021684, and the UCLA CTSI is funded under NIH/NCRR/NCATS Grant Number UL1TR000124.
The Clinical and Translational Science Institutes (CTSIs) of UCLA and the University of Minnesota announce the 2012 Cross-Institutional Awards for Health Disparities Research and Health Systems Change. The awards are designed to improve health and health care in diverse communities through productive partnerships among researchers, clinicians, and community-based organizations.
The Cross-Institutional Award for Health Disparities Research and Health Systems Change supports pilot projects that address health disparities and health systems problems of importance to Southern California and Minnesota. Awards are expected to lead to submission of an application for extramural funding. This opportunity will provide up to three, one-year awards of $50,000–$75,000 each.
Translational research is focused on “translating” basic scientific discoveries into health interventions, and then moving those interventions into clinical practice to improve patient care and population health. Translational research aims to accelerate the pace of discovery, speed the application of new knowledge to novel prevention strategies, diagnostics and treatments, and transfer these innovations to health care providers and the public.
Clinical and Translational Science Institutes (CTSIs) provide the research infrastructure to support translational research. The CTSIs support pilot studies, train young researchers, and engage schools and communities in health improvement. The CTSI program is led by the National Center for Advancing Translational Sciences, part of the National Institutes of Health.
An important goal of the CTSI program is to effectively engage communities in translational research. This RFA seeks projects in which community-based organizations participate fully with faculty in the research process. Research questions must be relevant to community needs and community organizations must be involved in the formulation, execution, analysis, interpretation and dissemination of the research.
The UCLA Older Americans Independence Center (OAIC) and the UCLA Clinical and Translational Science Institute (CTSI) are soliciting applications for the Rapid Grants Program for aging-related basic, clinical and health services research. Award size will range from $1,000 to $10,000, dependent on scope of work. The Principal Investigator must be a UCLA junior faculty member or advanced trainee. Priority will be given to investigators who have not been prior recipients of OAIC funding. Funds will be awarded for this opportunity as long as they are available. However, all funds must be spent by June, 30 2012.
For more information, please click here.
UCLA Clinical and Translational Science Institute-Los Angeles County Department of Health Services (LAC DHS) Collaboration Grants provide up to $30,000 for a period of one year to test solutions that enable LAC DHS to improve and increase delivery of high quality, patient-centered services without increasing costs. UCLA CTSI and LAC DHS anticipate making up to five (5) awards.
For information about deadlines, eligibility and requirements and the review process, please see the RFA.
This round of applications are due February 15, 2013 at 5:00 pm, 2013, Pacific Time. Click here for details and to apply.
Funding Opportunities Newsletter provided by the UCLA Strategic Research Initiatives.